Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sellas Life Sciences Group Inc (SLS)

Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Sellas Life Sciences Group Inc 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 USA

www.sellaslifesciences.com Employees: 15 P: 646-200-5278

Sector:

Medical

Description:

SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States.

Key Statistics

Overview:

Market Capitalization, $K 566,919
Enterprise Value, $K 552,929
Shares Outstanding, K 142,442
Float, K 140,448
% Float 98.60%
Short Interest, K 40,467
Short Float 28.41%
Days to Cover 7.07
Short Volume Ratio 0.52
% of Insider Shareholders 1.40%
% of Institutional Shareholders 17.38%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -30,880 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -6,790 K
EBIT, $ -26,930 K
EBITDA, $ -26,930 K

Growth:

1-Year Return 304.97%
3-Year Return 21.71%
5-Year Return -33.22%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 95.39%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.06 on 11/12/25
Next Earnings Date 03/19/26
Earnings Per Share ttm -0.28
EPS Growth vs. Prev Qtr 14.29%
EPS Growth vs. Prev Year 40.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-50 on 11/08/19

SLS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -95.20%
Return-on-Assets % -75.06%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 10.53
Book Value/Share 0.36
Interest Coverage -1.49
60-Month Beta 2.26
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar